Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrinn har blitt vist en uke etter primær vaksinasjonskurs for rhinotrakeitt, calicivirus, chlamydophila felis og panleukopeni-komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

virbac s.a. - levende dempet rabiesvirus, sag2-stamme - live viral vaksiner - raccoon dogs (nyctereutes procyonoides); red foxes (vulpes vulpes) - for aktiv immunisering av røde ræv og vaskehunder for å forhindre infeksjon med rabiesvirus. varigheten av beskyttelsen er på minst 6 måneder.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosteron - seksuelle dysfunksjoner, psykologisk - sex hormoner og modulatorer av genital systemet, - intrinsa er indisert for behandling av hypoactive seksuell lyst lidelse (hsdd) i bilateralt oophorectomised og hysterectomised (kirurgisk indusert overgangsalder) kvinner mottar samtidig estrogen terapi.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.

Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

ge healthcare as - flutemetamol (18f) - radionuclide imaging; alzheimer disease - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. vizamyl er en radiopharmaceutical legemiddel indikert for positron emisjon tomografi (pet) avbildningen av amyloid-β neuritic plakk tetthet i hjernen hos voksne pasienter med kognitiv svikt som blir vurdert for alzheimers sykdom (ad) og andre årsaker til kognitiv svikt. vizamyl bør brukes sammen med en klinisk vurdering. en negativ søk angir sparsom eller ingen plakk, som ikke er forenlig med diagnosen ad.

Norwe - Kinorwe - Statens legemiddelverk

abbvie as - deoksykolsyre - injeksjonsvæske, oppløsning - 10 mg/ ml

Norwe - Kinorwe - Statens legemiddelverk

mip pharma gmbh - ceftriaksonnatrium - pulver til infusjonsvæske, oppløsning - 2 g